Search research articles
Contact Us
Filters
Showing results (41-50 of 61) with videos related to
Page
of 7
Sort By:
European Heart Journal
|
August 30, 2020
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
Daniel Gaudet, Ewa Karwatowska-Prokopczuk, Seth J Baum, et al.
American Journal of Preventive Cardiology
|
August 25, 2020
Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology
Amit Khera, Seth J Baum, Ty J Gluckman, et al.
Journal of Clinical Lipidology
|
July 26, 2025
Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participants
Asia Sikora Kessler, T Michelle Brown, Emily Bratlee-Whitaker, et al.
Journal of Primary Care & Community Health
|
October 23, 2020
Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data
David W Dodick, Anand S Shewale, Richard B Lipton, et al.
Journal of Clinical Lipidology
|
July 28, 2022
Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia
Ewa Karwatowska-Prokopczuk, Jean-Claude Tardif, Daniel Gaudet, et al.
JAMA Cardiology
|
February 12, 2025
Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial
Robert S Rosenson, J Antonio G López, Daniel Gaudet, et al.
The New England Journal of Medicine
|
January 2, 2020
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas, Ewa Karwatowska-Prokopczuk, Ioanna Gouni-Berthold, et al.
The New England Journal of Medicine
|
November 7, 2022
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
Michelle L O'Donoghue, Robert S Rosenson, Baris Gencer, et al.
Nature Medicine
|
March 6, 2023
Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial
Robert S Rosenson, Daniel Gaudet, Christie M Ballantyne, et al.
Journal of the American College of Cardiology
|
August 21, 2024
The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results
Michelle L O'Donoghue, Robert S Rosenson, J Antonio G López, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 61) with videos related to
Sort By:
Page
of 7
European Heart Journal
|
August 30, 2020
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
Daniel Gaudet, Ewa Karwatowska-Prokopczuk, Seth J Baum, et al.
American Journal of Preventive Cardiology
|
August 25, 2020
Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology
Amit Khera, Seth J Baum, Ty J Gluckman, et al.
Journal of Clinical Lipidology
|
July 26, 2025
Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participants
Asia Sikora Kessler, T Michelle Brown, Emily Bratlee-Whitaker, et al.
Journal of Primary Care & Community Health
|
October 23, 2020
Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data
David W Dodick, Anand S Shewale, Richard B Lipton, et al.
Journal of Clinical Lipidology
|
July 28, 2022
Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia
Ewa Karwatowska-Prokopczuk, Jean-Claude Tardif, Daniel Gaudet, et al.
JAMA Cardiology
|
February 12, 2025
Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial
Robert S Rosenson, J Antonio G López, Daniel Gaudet, et al.
The New England Journal of Medicine
|
January 2, 2020
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas, Ewa Karwatowska-Prokopczuk, Ioanna Gouni-Berthold, et al.
The New England Journal of Medicine
|
November 7, 2022
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
Michelle L O'Donoghue, Robert S Rosenson, Baris Gencer, et al.
Nature Medicine
|
March 6, 2023
Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial
Robert S Rosenson, Daniel Gaudet, Christie M Ballantyne, et al.
Journal of the American College of Cardiology
|
August 21, 2024
The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results
Michelle L O'Donoghue, Robert S Rosenson, J Antonio G López, et al.
Page
of 7